Table 3.
Outcomes of Anti-Cancer Chemotherapy (Anti-CCT) and Anti-MTB Chemotherapy
| Characteristic | Patients | |||
|---|---|---|---|---|
| All | LC (SCLC/NSCLC) | CRC | Other | |
| (n = 30) | (n = 15, 5/10) | (n = 10) | (n = 5) | |
| Initial concurrent anti-CCT regimen, n | ||||
| Intensive cytotoxic regimen and targeted agenta | 4 | 0 | 3 | 1 |
| Intensive cytotoxic regimenb | 19 | 10 (5/5) | 6 | 3 |
| Single targeted agentc | 2 | 2 (0/2) | 0 | 0 |
| Single cytotoxic agentd | 5 | 3 (0/3) | 1 | 1 |
| Best response on anti-CCT after commencing concurrent chemotherapy, n | ||||
| CR | 1 | 0 | 1 | 0 |
| PR | 10 | 5 (4/1) | 3 | 2 |
| SD | 5 | 2 (0/2) | 3 | 0 |
| PD | 6 | 4 (0/4) | 2 | 0 |
| NE | 8 | 4 (1/3) | 1 | 3 |
| ORR (%)e | 36.7 | 33.3 (80.0/10.0) | 40.0 | 40.0 |
| Main anti-MTB chemotherapy, n | ||||
| 2HREZ/7HRf | 15 | 8 (3/5) | 4 | 3 |
| 6HRE/6HRg | 7 | 2 (0/2) | 4 | 1 |
| Levofloxacin-based | 8 | 5 (2/3) | 2 | 1 |
| Duration of anti-MTB treatment (days), median (range) | 275.0 (72–637) | 274.0 (90–469) [274 (183–469)/255 (90–310)] | 259.0 (72–539) | 368.0 (273–637) |
| Duration of concurrent chemotherapy (days), median (range) | 157.5 (13–408) | 117.0 (20–245) [93 (20–207)/121 (48–245)] | 168.5 (13–408) | 155.0 (51–376) |
| MTB treatment outcomes, n (%) | All | LC | CRC | Other |
| Cured | 20 (66.7) | 10 (66.7) | 6 (60.0) | 4 (80.0) |
| Completed | 1 (3.3) | 0 | 1 (10.0) | 0 |
| Died | 9 (30) | 5 (33.3) | 3 (30.0) | 1 (20.0) |
| Failed | 0 | 0 | 0 | 0 |
| Not evaluated | 0 | 0 | 0 | 0 |
| Success (%)h | 70.0 | 66.7 | 70.0 | 80.0 |
Abbreviations CI confidence interval, CR complete response, CRC colorectal cancer, E ethambutol, EGFR-TKI epidermal growth factor receptor-tyrosine kinase inhibitor, H isoniazid, LC lung cancer, MTB Mycobacterium tuberculosis, NE not evaluable, ORR overall response rate, PD progressive disease, PR partial response, R rifampicin, SD stable disease, Z pyrazinamide
aTwo cytotoxic agents combined with targeted therapy (bevacizumab or trastuzumab)
bTwo cytoxic agents
cErlotinib
dSingle cytoxic agent (S-1, vinorelbine, or pemetrexed)
eCR + PR
fDaily drug combination containing HREZ for 2 months, followed by daily HR for 7 months
gDaily drug combination containing HRE for 6 months, followed by HR for 6 months
hCured + completed